<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38256566</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>The Effect of Sodium-Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">431</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13020431</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is no clinical evidence about the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on diabetic patients who have been diagnosed with coronavirus disease 19 (COVID-19).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The dataset is based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea from January, 2018 to April, 2022. Among 9,822,577 patients who were involved in the claims, diabetic patients were divided into two groups based on whether they had a prescription for an SGLT2 inhibitor. The primary outcome was major adverse cardiac and cerebrovascular events (MACCEs), which were a composite of all-cause mortality, myocardial infarction, stroke, and revascularization over 90 days.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 172,682 patients was analyzed. In the propensity score-matched analysis, the rate of MACCE was lower in the SGLT2 inhibitor group compared to the non-SGLT2 inhibitor group (0.89% vs. 1.31%; hazard ratio, 0.71; 95% confidence interval, 0.53-0.94; <i>p</i> =0.020). Each of the MACCEs showed no differences between the two groups. The rate of pneumonia was similar between the two groups (4.45% vs. 4.39%; hazard ratio, 1.06; 95% confidence interval, 0.91-1.16; <i>p</i> = 0.620).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the diabetic patients who were diagnosed with COVID-19, SGLT2 inhibitors were associated with improved clinical outcomes in terms of MACCEs. SGLT2 inhibitors might be considered for prescription to diabetic patients in the current context of long COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Kyoung Ree</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Kwang Jin</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon 24341, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Bum Sung</ForeName><Initials>BS</Initials><Identifier Source="ORCID">0000-0002-3864-419X</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Konkuk University Medical Center, Seoul 05029, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seunghwa</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5508-7519</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Wiltse Memorial Hospital, Suwon 16480, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>2023 Kangwon National University Hospital Grant</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MACCE</Keyword><Keyword MajorTopicYN="N">SGLT2 inhibitor</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38256566</ArticleId><ArticleId IdType="pmc">PMC10815946</ArticleId><ArticleId IdType="doi">10.3390/jcm13020431</ArticleId><ArticleId IdType="pii">jcm13020431</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Lancet. Long COVID: 3 Years in. Lancet. 2023;401:795. doi: 10.1016/S0140-6736(23)00493-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00493-2</ArticleId><ArticleId IdType="pmc">PMC9998094</ArticleId><ArticleId IdType="pubmed">36906338</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R., Hussain A., Misra A. Diabetes and COVID-19: Evidence, Current Status and Unanswered Research Questions. Eur. J. Clin. Nutr. 2020;74:864&#x2013;870. doi: 10.1038/s41430-020-0652-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41430-020-0652-1</ArticleId><ArticleId IdType="pmc">PMC7220586</ArticleId><ArticleId IdType="pubmed">32404898</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the Cardiovascular System. Nat. Rev. Cardiol. 2020;17:259&#x2013;260. doi: 10.1038/s41569-020-0360-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0360-5</ArticleId><ArticleId IdType="pmc">PMC7095524</ArticleId><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorchenko Y., Zimba O. Comorbidities in the COVID-19 Pandemic: Scopus-Based Bibliometric Analysis. J. Korean Med. Sci. 2023;38:e93. doi: 10.3346/jkms.2023.38.e93.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2023.38.e93</ArticleId><ArticleId IdType="pmc">PMC10027540</ArticleId><ArticleId IdType="pubmed">36942396</ArticleId></ArticleIdList></Reference><Reference><Citation>Raisi-Estabragh Z., Cooper J., Salih A., Raman B., Lee A.M., Neubauer S., Harvey N.C., Petersen S.E. Cardiovascular Disease and Mortality Sequelae of COVID-19 in the UK Biobank. Heart. 2022;109:119&#x2013;126. doi: 10.1136/heartjnl-2022-321492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2022-321492</ArticleId><ArticleId IdType="pmc">PMC9811071</ArticleId><ArticleId IdType="pubmed">36280346</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-Term Cardiovascular Outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunwald E. SGLT2 Inhibitors: The Statins of the 21st Century. Eur. Heart J. 2022;43:1029&#x2013;1030. doi: 10.1093/eurheartj/ehab765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab765</ArticleId><ArticleId IdType="pubmed">34741610</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., Furtado R.H.M., et al. SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials. Lancet. 2019;393:31&#x2013;39. doi: 10.1016/S0140-6736(18)32590-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32590-X</ArticleId><ArticleId IdType="pubmed">30424892</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainsbury C., Wang J., Gokhale K., Acosta-Mena D., Dhalla S., Byne N., Chandan J.S., Anand A., Cooper J., Okoth K., et al. Sodium-Glucose Co-Transporter-2 Inhibitors and Susceptibility to COVID-19: A Population-Based Retrospective Cohort Study. Diabetes Obes. Metab. 2021;23:263&#x2013;269. doi: 10.1111/dom.14203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14203</ArticleId><ArticleId IdType="pmc">PMC7537530</ArticleId><ArticleId IdType="pubmed">32991065</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale R.J., Valtis Y.K., McDonnell M.E., Palermo N.E., Fisher N.D.L. Euglycemic Diabetic Ketoacidosis with COVID-19 Infection in Patients with Type 2 Diabetes Taking SGLT2 Inhibitors. AACE Clin. Case Rep. 2021;7:10&#x2013;13. doi: 10.1016/j.aace.2020.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aace.2020.11.019</ArticleId><ArticleId IdType="pmc">PMC7833657</ArticleId><ArticleId IdType="pubmed">33521255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosiborod M.N., Esterline R., Furtado R.H.M., Oscarsson J., Gasparyan S.B., Koch G.G., Martinez F., Mukhtar O., Verma S., Chopra V., et al. Dapagliflozin in Patients with Cardiometabolic Risk Factors Hospitalised with COVID-19 (DARE-19): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Diabetes Endocrinol. 2021;9:586&#x2013;594. doi: 10.1016/S2213-8587(21)00180-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00180-7</ArticleId><ArticleId IdType="pmc">PMC8294807</ArticleId><ArticleId IdType="pubmed">34302745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.W., Kim C., Kim K.H., Lee Y., Yu D.H., Yun J., Baek H., Park R.W., You S.C. Scalable Infrastructure Supporting Reproducible Nationwide Healthcare Data Analysis toward FAIR Stewardship. Sci. Data. 2023;10:674. doi: 10.1038/s41597-023-02580-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-023-02580-7</ArticleId><ArticleId IdType="pmc">PMC10550904</ArticleId><ArticleId IdType="pubmed">37794003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G., Kiefer R.C., Sharma D.K., Prud&#x2019;hommeaux E., Solbrig H.R. A Consensus-Based Approach for Harmonizing the OHDSI Common Data Model with HL7 FHIR. Stud. Health Technol. Inform. 2017;245:887&#x2013;891. doi: 10.1016/j.physbeh.2017.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physbeh.2017.03.040</ArticleId><ArticleId IdType="pmc">PMC5939955</ArticleId><ArticleId IdType="pubmed">29295227</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Florencio L.L., Cuadrado M.L., Plaza-Manzano G., Navarro-Santana M. Prevalence of Post-COVID-19 Symptoms in Hospitalized and Non-Hospitalized COVID-19 Survivors: A Systematic Review and Meta-Analysis. Eur. J. Intern. Med. 2021;92:55&#x2013;70. doi: 10.1016/j.ejim.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Elze M.C., Gregson J., Baber U., Williamson E., Sartori S., Mehran R., Nichols M., Stone G.W., Pocock S.J. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J. Am. Coll. Cardiol. 2017;69:345&#x2013;357. doi: 10.1016/j.jacc.2016.10.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.10.060</ArticleId><ArticleId IdType="pubmed">28104076</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K., Valabhji J., Misra S. Diabetes and the COVID-19 Pandemic. Diabetologia. 2023;66:255&#x2013;266. doi: 10.1007/s00125-022-05833-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05833-z</ArticleId><ArticleId IdType="pmc">PMC9685151</ArticleId><ArticleId IdType="pubmed">36418578</ArticleId></ArticleIdList></Reference><Reference><Citation>Unsworth R., Wallace S., Oliver N.S., Yeung S., Kshirsagar A., Naidu H., Kwong R.M.W., Kumar P., Logan K.M. New-Onset Type 1 Diabetes in Children during COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care. 2020;43:e170&#x2013;e171. doi: 10.2337/dc20-1551.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-1551</ArticleId><ArticleId IdType="pubmed">32816997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamrath C., M&#xf6;nkem&#xf6;ller K., Biester T., Rohrer T.R., Warncke K., Hammersen J., Holl R.W. Ketoacidosis in Children and Adolescents with Newly Diagnosed Type 1 Diabetes during the COVID-19 Pandemic in Germany. JAMA. 2020;324:801. doi: 10.1001/jama.2020.13445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.13445</ArticleId><ArticleId IdType="pmc">PMC7372511</ArticleId><ArticleId IdType="pubmed">32702751</ArticleId></ArticleIdList></Reference><Reference><Citation>Maayah Z.H., Ferdaoussi M., Takahara S., Soni S., Dyck J.R.B. Empagliflozin Suppresses Inflammation and Protects against Acute Septic Renal Injury. Inflammopharmacology. 2021;29:269&#x2013;279. doi: 10.1007/s10787-020-00732-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00732-4</ArticleId><ArticleId IdType="pubmed">32564182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.-F., Chan Y.-H., Chuang C., Li P.-R., Yeh Y.-H., Hsiao F.-C., Peng J.-R., See L.-C. Cardiovascular, Renal, and Lower Limb Outcomes in Patients with Type 2 Diabetes after Percutaneous Coronary Intervention and Treated with Sodium&#x2013;Glucose Cotransporter 2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors. Eur. Heart J. Cardiovasc. Pharmacother. 2023;9:301. doi: 10.1093/ehjcvp/pvad004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvad004</ArticleId><ArticleId IdType="pubmed">36639127</ArticleId></ArticleIdList></Reference><Reference><Citation>Tereshchenko L.G., Bishop A., Fisher-Campbell N., Levene J., Morris C.C., Patel H., Beeson E., Blank J.A., Bradner J.N., Coblens M., et al. Risk of Cardiovascular Events after COVID-19. Am. J. Cardiol. 2022;179:102&#x2013;109. doi: 10.1016/j.amjcard.2022.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2022.06.023</ArticleId><ArticleId IdType="pmc">PMC9282909</ArticleId><ArticleId IdType="pubmed">35843735</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox S.E., Li G., Akmatbekov A., Harbert J.L., Lameira F.S., Brown J.Q., Heide R.S.V. Unexpected Features of Cardiac Pathology in COVID-19 Infection. Circulation. 2020;142:1123&#x2013;1125. doi: 10.1161/CIRCULATIONAHA.120.049465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049465</ArticleId><ArticleId IdType="pubmed">32689809</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D., Plein S., O&#x2019;Donnell J.S., Sharif K., Bridgewood C. Increased Cardiovascular Mortality in African Americans with COVID-19. Lancet Respir. Med. 2020;8:649&#x2013;651. doi: 10.1016/S2213-2600(20)30244-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30244-7</ArticleId><ArticleId IdType="pmc">PMC7255150</ArticleId><ArticleId IdType="pubmed">32473125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowie M.R., Fisher M. SGLT2 Inhibitors: Mechanisms of Cardiovascular Benefit beyond Glycaemic Control. Nat. Rev. Cardiol. 2020;17:761&#x2013;772. doi: 10.1038/s41569-020-0406-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0406-8</ArticleId><ArticleId IdType="pubmed">32665641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M.-Z., Chandramouli C., Wong P.-F., Chan Y.-H., Li H.-L., Yu S.-Y., Tse Y.-K., Ren Q.-W., Yu S.-Y., Tse H.-F., et al. Risk of Sepsis and Pneumonia in Patients Initiated on SGLT2 Inhibitors and DPP-4 Inhibitors. Diabetes Metab. 2022;48:101367. doi: 10.1016/j.diabet.2022.101367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2022.101367</ArticleId><ArticleId IdType="pubmed">35753654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossi A.C., Forloni F., Colombelli P.L. Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (NCoV) Infection: No Little Help from Our Friends. Diabetes Ther. 2020;11:1605&#x2013;1606. doi: 10.1007/s13300-020-00844-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13300-020-00844-8</ArticleId><ArticleId IdType="pmc">PMC7244936</ArticleId><ArticleId IdType="pubmed">32447736</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>